Sona Nanotech Inc. (SNANF)
| Market Cap | 31.12M -35.7% |
| Revenue (ttm) | n/a |
| Net Income | -2.02M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,323 |
| Open | 0.2007 |
| Previous Close | n/a |
| Day's Range | 0.2007 - 0.2595 |
| 52-Week Range | 0.1868 - 0.5903 |
| Beta | 1.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 25, 2026 |
About Sona Nanotech
Sona Nanotech Inc. operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor targeting activity, anti-bacterial activity, and drug delivery vehicle, as well as diagnostics, such as diagnostic markers for imaging and immunoassay and biosensing. It also engages in the development of targeted hyperthermia therapy, a photo thermal therapy for the treatment of cancer tumors; and diagnostic tools comprising l... [Read more]
News
Sona Nanotech to Present at the OTC Markets' Life Sciences Virtual Investor Forum On September 17th
HALIFAX, Nova Scotia, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF), an oncology company developing a therapy to increase the limited efficacy of immunotherapy drug...
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses - confirmed in a representative tumor biopsy - all within tw...
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon...
Sona Provides Update on First-In-Human Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therap...
Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval
Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapie...
First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy
Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025)...
Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapie...
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
First Patients Expected to be Enrolled This Month Halifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused lif...
Sona Successfully Completes FDA-Required Toxicity Study
Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce positive results from a required preclinical safety...
Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin te...
BioVaxys and Sona Nanotech Enter Research Collaboration
Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) ...
Sona Nanotech Announces Annual Options Grants
Halifax, Nova Scotia--(Newsfile Corp. - May 1, 2025) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive stock options under th...
Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model
Halifax, Nova Scotia--(Newsfile Corp. - March 19, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to provide updated data confirming efficacy of its Targeted H...
Sona Nanotech Inc. CEO David Regan to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / David Regan, CEO of Sona Nanotech Inc. (OTCQB:SNANF)(CSE:SONA), will be presenting at this year's Investor Summit Virtual on March 11th at 11:30am ET. ...
Sona Nanotech's Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference
Halifax, Nova Scotia--(Newsfile Corp. - February 12, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its recently published findings from its ...
Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal
Halifax, Nova Scotia--(Newsfile Corp. - January 13, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that the now complete findings from our previou...
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study
Halifax, Nova Scotia--(Newsfile Corp. - December 11, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targe...
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update
Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagl...
Sona Nanotech Issued Patent and Appoints New Board Member
Halifax, Nova Scotia--(Newsfile Corp. - October 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No. 12117447 by the...
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - October 9, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock opt...
Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds
Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its non-brokered private...
Sona Nanotech Closes Private Placement Financing to Raise $1,500,000 in Gross Proceeds and Announces Additional Financing
Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its non-brokered private ...
Sona Nanotech to Arrange Private Placement Financing
Halifax, Nova Scotia--(Newsfile Corp. - July 31, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that it plans to raise up to $1,500,000 through a ...
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study
Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recent...
Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer
Halifax, Nova Scotia--(Newsfile Corp. - June 20, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") d...